Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSantamarina Pérez, Estevo
dc.contributor.authorAlpuente Ruiz, Alicia
dc.contributor.authorMaisterra Santos, Olga
dc.contributor.authorSueiras Gil, Maria
dc.contributor.authorSarria Estrada, Silvana Isabel
dc.contributor.authorGuzmán García, Lorena Carolina
dc.contributor.authorAbraira del Fresno, Laura
dc.contributor.authorSalas Puig, Xavier
dc.contributor.authorToledo Argany, Manuel
dc.date.accessioned2019-04-09T11:22:06Z
dc.date.available2019-04-09T11:22:06Z
dc.date.issued2019-02-07
dc.identifier.citationSantamarina E, Alpuente A, Maisterra O, Sueiras M, Sarria S, Guzman L, et al. Perampanel: A therapeutic alternative in refractory status epilepticus associated with MELAS syndrome. Epilepsy Behav Case Report. 2019;11:92–5.
dc.identifier.issn2213-3232
dc.identifier.urihttp://hdl.handle.net/11351/4033
dc.descriptionMELAS; Perampanel; Status epilepticus
dc.description.abstractTo our knowledge, there are no reports of status epilepticus (SE) associated with mitochondrial diseases and treated with perampanel (PER). We present three cases of patients with refractory SE associated with MELAS syndrome who responded favorably to PER. All cases were diagnosed as non-convulsive SE (focal without impairment of level of consciousness). After an initial treatment with other anti-seizure drugs, PER was added in all cases (8, 16 and 12 mg) and cessation of SE was observed within the next 4-8 hours. All the cases involved a stroke-like lesion present on brain MRI. In our patients, PER was an effective option in SE associated with MELAS syndrome.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEpilepsy and Behavior Case Reports;11
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEpilèpsia - Tractament
dc.subjectEncefalitis - Tractament
dc.subjectPiridina
dc.subject.meshStatus Epilepticus
dc.subject.meshMELAS Syndrome
dc.subject.mesh/drug therapy
dc.subject.meshPyridones
dc.titlePerampanel: A therapeutic alternative in refractory status epilepticus associated with MELAS syndrome
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ebcr.2019.01.008
dc.subject.decsestado epiléptico
dc.subject.decssíndrome MELAS
dc.subject.decs/tratamiento farmacológico
dc.subject.decspiridonas
dc.relation.publishversionhttps://www.sciencedirect.com/science/article/pii/S2213323218301695?via%3Dihub#!
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Santamarina E, Alpuente A]Unitat d’Epilèpsia, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Maisterra O] Unitat Neurovascular, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Sueiras M] Unitat d’Electroencefalografia, Servei de Neurofisiologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Sarria S] Unitat MRI, Servei de Neuroradiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Guzman L] Unitat d’Electroencefalografia, Servei de Neurofisiologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Abraira L, Salas-Puig J, Toledo M] Unitat d’Epilèpsia, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
dc.identifier.pmid30834194
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record